Literature DB >> 2230885

The calculation of received dose intensity.

W M Hryniuk, M Goodyear.   

Abstract

Mesh：

Year:  1990        PMID： 2230885     DOI： 10.1200/JCO.1990.8.12.1935

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  40 in total

1.  Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels.

Authors:  C F Pollera; A Ceribelli; M Crecco; C Oliva; F Calabresi
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

2.  Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.

Authors:  Daphne Y Xiao; Suhong Luo; Katiuscia O'Brian; Arun Ganti; Peter Riedell; Kristen M Sanfilippo; Ryan C Lynch; Weijian Liu; Kenneth R Carson
Journal:  Am J Hematol       Date:  2016-07-22       Impact factor: 10.047

3.  Impact of R-CHOP dose intensity on survival outcomes in diffuse large B-cell lymphoma: a systematic review.

Authors:  Edward J Bataillard; Chan Yoon Cheah; Matthew J Maurer; Arushi Khurana; Toby A Eyre; Tarec Christoffer El-Galaly
Journal:  Blood Adv       Date:  2021-05-11

4.  Febrile neutropenic events in cancer patients: treatment for fever and neutropenia in young adult patients during intensive chemotherapy for solid tumours.

Authors:  M Nobbenhuis; F J Cleton
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Age-Associated Hematological Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel in Clinical Practice.

Authors:  Marie-Rose B S Crombag; Aurelia H M de Vries Schultink; Jacobine G C van Doremalen; Hans-Martin Otten; Andries M Bergman; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

6.  Clinical relevance of the dose of cytarabine in the upfront treatment of primary CNS lymphomas with methotrexate-cytarabine combination.

Authors:  Andrés J M Ferreri; Giada Licata; Marco Foppoli; Gaetano Corazzelli; Emanuele Zucca; Caterina Stelitano; Francesco Zaja; Sergio Fava; Rossella Paolini; Alberto Franzin; Letterio S Politi; Maurilio Ponzoni; Michele Reni
Journal:  Oncologist       Date:  2011-02-23

7.  The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.

Authors:  Jonathan W Friedberg; Julie M Vose; Jennifer L Kelly; Faith Young; Steven H Bernstein; Derick Peterson; Lynn Rich; Susan Blumel; Nicole K Proia; Jane Liesveld; Richard I Fisher; James O Armitage; Steven Grant; John P Leonard
Journal:  Blood       Date:  2011-01-14       Impact factor: 22.113

8.  Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival.

Authors:  Elisa V Bandera; Valerie S Lee; Lorna Rodriguez-Rodriguez; C Bethan Powell; Lawrence H Kushi
Journal:  Clin Cancer Res       Date:  2016-08-12       Impact factor: 12.531

9.  Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.

Authors:  William Jacot; Marie-Cécile Gerlotto-Borne; Simon Thezenas; Stéphane Pouderoux; Sylvain Poujol; Mahdi About; Gilles Romieu
Journal:  BMC Cancer       Date:  2010-06-04       Impact factor: 4.430

10.  Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.

Authors:  James P Carroll; Melinda M Protani; Linda Nguyen; Matthew E Cheng; Mike Fay; Mohamed Saleem; Praga S Pillay; Euan Walpole; Jennifer H Martin
Journal:  Med Oncol       Date:  2014-02-19       Impact factor: 3.064
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.